-+ 0.00%
-+ 0.00%
-+ 0.00%

Navamedic Extends Nordic Rights for Mysimba Obesity Drug

MT Newswires·10/20/2026 05:04:04
Listen to the news
05:04 AM EDT, 10/20/2026 (MT Newswires) -- Navamedic (NAVA.OL) extended its Nordic distribution and marketing rights for the Mysimba obesity drug for another five years. The Nordic healthcare products provider said Tuesday that the agreement with Mysimba's new owner, Azurity Pharmaceuticals, largely maintains the original contract terms and includes an upfront licensing fee. The extension will take effect on April 26, 2027.